MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda.
Pediatr Allergy Immunol. 2011 May;22(3):305-12. doi: 10.1111/j.1399-3038.2010.01122.x. Epub 2011 Jan 23.
Allergy is commoner in developed than in developing countries. Chronic worm infections show inverse associations with allergy, and prenatal exposures may be critical to allergy risk.
To determine whether anthelminthic treatment during pregnancy increases the risk of allergy in infancy.
A randomised, double-blind, placebo-controlled trial on treatment in pregnancy with albendazole versus placebo and praziquantel versus placebo was conducted in Uganda, with a 2 × 2 factorial design; 2507 women were enrolled; infants' allergy events were recorded prospectively. The main outcome was doctor-diagnosed infantile eczema.
Worms were detected in 68% of women before treatment. Doctor-diagnosed infantile eczema incidence was 10.4/100 infant years. Maternal albendazole treatment was associated with a significantly increased risk of eczema [Cox HR (95% CI), p: 1.82 (1.26-2.64), 0.002]; this effect was slightly stronger among infants whose mothers had no albendazole-susceptible worms than among infants whose mothers had such worms, although this difference was not statistically significant. Praziquantel showed no effect overall but was associated with increased risk among infants of mothers with Schistosoma mansoni [2.65 (1.16-6.08), interaction p = 0.02]. In a sample of infants, skin prick test reactivity and allergen-specific IgE were both associated with doctor-diagnosed eczema, indicating atopic aetiology. Albendazole was also strongly associated with reported recurrent wheeze [1.58 (1.13-2.22), 0.008]; praziquantel showed no effect.
The detrimental effects of treatment suggest that exposure to maternal worm infections in utero may protect against eczema and wheeze in infancy. The results for albendazole are also consistent with a direct drug effect. Further studies are required to investigate mechanisms of these effects, possible benefits of worms or worm products in primary prevention of allergy, and the possibility that routine deworming during pregnancy may promote allergic disease in the offspring.
过敏在发达国家比在发展中国家更为常见。慢性蠕虫感染与过敏呈负相关,产前暴露可能对过敏风险至关重要。
确定怀孕期间驱虫治疗是否会增加婴儿期过敏的风险。
在乌干达进行了一项随机、双盲、安慰剂对照试验,研究了怀孕期间用阿苯达唑与安慰剂和吡喹酮与安慰剂进行治疗的效果,采用 2×2 析因设计;共纳入 2507 名女性;前瞻性记录婴儿过敏事件。主要结局是医生诊断的婴儿湿疹。
治疗前 68%的女性体内检测到蠕虫。医生诊断的婴儿湿疹发病率为每 100 婴儿年 10.4 例。母亲接受阿苯达唑治疗与湿疹风险显著增加相关[Cox HR(95%CI),p:1.82(1.26-2.64),0.002];在母亲没有阿苯达唑敏感蠕虫的婴儿中,这种效果略强,但与母亲有此类蠕虫的婴儿相比,差异无统计学意义。总体而言,吡喹酮没有效果,但与母亲有曼氏血吸虫的婴儿的风险增加相关[2.65(1.16-6.08),交互 p=0.02]。在一个婴儿样本中,皮肤点刺试验反应性和过敏原特异性 IgE 均与医生诊断的湿疹相关,表明存在特应性病因。阿苯达唑还与报告的反复喘息强烈相关[1.58(1.13-2.22),0.008];吡喹酮没有效果。
治疗的有害影响表明,子宫内接触母体蠕虫感染可能有助于预防婴儿期湿疹和喘息。阿苯达唑的结果也与直接药物作用一致。需要进一步研究这些影响的机制,研究蠕虫或蠕虫产物在预防过敏方面的潜在益处,以及怀孕期间常规驱虫是否可能会促进后代发生过敏性疾病。